{
    "organizations": [],
    "uuid": "d8464f20c59abe3da723111045f816d26990ac15",
    "author": "",
    "url": "https://www.reuters.com/article/brief-bluebird-bio-expects-three-regulat/brief-bluebird-bio-expects-three-regulatory-filings-by-end-2019-idUSL1N1P40T0",
    "ord_in_thread": 0,
    "title": "BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 9, 2018 / 4:30 PM / Updated 39 minutes ago BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019 Reuters Staff \nJan 9 (Reuters) - Bluebird Bio Inc: \n* BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019 \n* BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018 \n* BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019 Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)",
    "published": "2018-01-09T18:28:00.000+02:00",
    "crawled": "2018-01-09T18:47:19.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "bio",
        "expects",
        "three",
        "regulatory",
        "filing",
        "end",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "bluebird",
        "bio",
        "inc",
        "bluebird",
        "bio",
        "ceo",
        "say",
        "expects",
        "three",
        "regulatory",
        "filing",
        "end",
        "bluebird",
        "see",
        "filing",
        "approval",
        "beta",
        "thalassemia",
        "bluebird",
        "bio",
        "see",
        "filing",
        "u",
        "eu",
        "approval",
        "b2121",
        "multiple",
        "myeloma",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "reporting",
        "bill",
        "berkrot"
    ]
}